Quantinno Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.81M Buy
89,978
+68,607
+321% +$1.84M ﹤0.01% 2271
2026
Q2
$541K Buy
21,371
+6,039
+39% +$133K ﹤0.01% 2942
2026
Q1
$341K Buy
15,332
+5,244
+52% +$125K ﹤0.01% 2964
2025
Q4
$269K Sell
10,088
-1,112
-10% -$26.6K ﹤0.01% 2894
2025
Q3
$239K Buy
+11,200
New +$265K ﹤0.01% 2634

Other funds holding ACAD

Quantinno Capital Management's ACAD Position: Q3 2026 in Review

Quantinno Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 321% in Q3 2026, buying an estimated $1.84M and bringing the position to 89,978 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

Quantinno Capital Management first reported a position in ACAD in Q3 2025 and has held it in 5 quarters since. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Quantinno Capital Management held 89,978 shares of Acadia Pharmaceuticals worth $1.81M as of Q3 2026.
  • Quantinno Capital Management bought 68,607 Acadia Pharmaceuticals shares in Q3 2026, an estimated $1.84M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Quantinno Capital Management's portfolio in Q3 2026, its #2271 holding.
  • Quantinno Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Quantinno Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.